(CercleFinance.com) – Roche presents the latest advances in immunotherapies in non-Hodgkin lymphoma.
Data on experimental CD20xCD3 bispecific antibodies and new combined treatment regimens with Polivy showed increased clinical benefits for people with non-Hodgkin lymphoma in early studies.
This data will be presented at the ASCO 2021 annual meeting from June 4-8, 2021.
‘People with difficult-to-treat blood cancers such as non-Hodgkin lymphoma still need more options to improve outcomes,’ said Levi Garraway, MD, Ph.D., Roche medical director and head of global product development.
‘We are encouraged by the promising data from our emerging bispecific T-cell-engaging antibodies, mosunetuzumab and glofitamab, and the antibody-drug conjugate, Polivy, which demonstrate the potential of these new immunotherapeutic approaches for various patient groups. ‘
– .
